Pharmaceuticals & life sciences

PwC’s global network of pharmaceutical, biotech and medtech experts works with you to define and deliver effective solutions to the complex challenges affecting your business in all areas from innovation to regulation and patient engagement.

How we can help

PwC's pharmaceuticals and life sciences practice helps pharmaceutical, biotech and medical device clients develop future focused business strategies and to implement the time critical programmes and procedures essential to success within worldwide regulatory frameworks.

How PwC can help

The environment in which Pharmaceutical and Life Sciences companies operate is increasingly challenging, being driven by a more and more demanding healthcare agenda. The global need for innovative, cost effective medicines continues to rise whilst regulators, payers, health care providers and patients are demanding greater value for money, proven effectiveness of products, more transparency and access to information. To meet these demands companies are seeking ways to improve R&D productivity, increase the efficiency of its operations, rationalise spending on sales and marketing and enhance financial performance.

Working closely with our clients, ranging from small entrepreneurial life science companies to large global corporations, we aim to achieve increased performance by improving the efficiency and effectiveness of a company’s key business operations.

Across the whole Pharmaceutical and Life Sciences value chain, PwC's trusted consultants and professional advisors use their wealth of industry based experience, knowledge and expertise to help our clients evaluate their strategic business options, improve management and control, and identify cost saving initiatives.

Manufacturing

A combination of regulatory, market, scientific, and technological forces is likely to mean that pharmaceutical manufacturing will undergo rapid change in the next five to ten years. Many companies are already investing in change projects, but they are often piecemeal and not accompanied by a clear manufacturing vision. The absence of such a vision also means that companies sometimes feel caught between ‘big leap’ and more incremental changes. In fact, incremental change is vital to achieve a longer term 'big leap.' But, in the absence of a manufacturing vision, companies find themselves with no roadmap. The consequence is that changes are made in relative isolation without maximising their potential incremental contribution to longer term improvement or, worse, moving the company further away from the manufacturing it will need in the future. There is a need for companies to more consistently align investment in IT and manufacturing with their vision of the manufacturing that will be needed in the future. In doing so, companies will be able to ensure that investments don't just deliver specific gains, but also help accelerate the company's progress toward longer term goals. We can help companies achieve the change required and their goals by utilising our firm's in-depth industry expertise.

Contact us

Bruce Scott

Bruce Scott

Territory Leader, PwC Jamaica

Tel: 876 932 8335

Follow us